May 23, 2024

Lisata Secures EMA Waiver for Pancreatic Cancer Treatment

Clinical stage pharmaceutical company, Lisata Therapeutics, Inc. (Nasdaq: LSTA), has reached an agreement with the European Medicines Agency (EMA) on a Pediatric Investigation Plan for Lisata’s lead investigational product, certepetide, in pancreatic cancer. The EMA has agreed to a product-specific full pediatric waiver for certepetide in pancreatic cancer, on the grounds that pancreatic cancer occurs… [Read More]
May 22, 2024

Aligos Therapeutics Advances “Compelling Potential Treatment Option” in MASH

Aligos Therapeutics, Inc. (Nasdaq: ALGS) has completed enrollment in a Phase 2a clinical study for a metabolic dysfunction-associated steatohepatitis (MASH) therapeutic, with topline safety and efficacy data anticipated in early Q4 2024. The company is evaluating ALG-055009, a best-in-class thyroid hormone receptor beta (THR-ß) agonist, which has demonstrated safety and efficacy in a Phase 1… [Read More]
May 22, 2024

SunPower (SPWR) Now Sells the Tesla Powerwall 3; Investors Consider It a Bright Idea as Shares Trade Up ~20%

America’s top-rated residential solar energy company, SunPower Corporation (SPWR)  announced it will now offer the Tesla Powerwall 3 as part of its curated selection of high-quality and affordable solar and storage products. “Homeowners are increasingly turning to battery storage to protect themselves against ongoing utility rate hikes and grid outages. We witnessed record-breaking battery storage… [Read More]
Oil pumps under a sunset sky.
May 22, 2024

Formation Minerals (FOMI) Executes on Strategic Acquisition Strategy Through Recent Sale of Assets

Emerging oil and gas company, Formation Minerals, Inc. (FOMI) announced the sale of five non-core lower performing assets for $140,000 to a private buyer. The sale was completed on May 21, 2024. This highlights the company’s portfolio management abilities and execution of its strategic acquisition strategy. Formation’s strategy focuses on buying low-cost assets that monetize… [Read More]
May 21, 2024

Biodexa Shares Soar 128% on Positive Phase 2 Results in Rare Disease Trial

Shares in Biodexa Pharmaceuticals (Nasdaq: BDRX) soared 128% on Tuesday after the company reported positive Phase 2 clinical trial results from its newly licenses eRapa™ in Familial Adenomatous Polyposis (FAP) at the 2024 Digestive Disease Week Annual Meeting. The company topped the PRISM Emerging Pharmaceuticals Index throughout Tuesday’s trading session. In April 2024, Biodexa entered… [Read More]